Parkinson's Disease

In 1817, the London surgeon James Parkinson published An Essay on the Shaking Palsy, describing six patients with a previously unrecognized syndrome: resting tremor, rigidity, bradykinesia (slowness of movement), postural instability. The disease that bears his name now affects roughly 10 million people worldwide, and its incidence rises steeply with age; it is the second most common neurodegenerative disorder, after Alzheimer's. Its strangest feature is what underlies the symptoms: by the time motor signs first appear, roughly 80% of the dopamine-producing neurons in a small midbrain nucleus have already died. Stranger still, the visible tremor is often the late chapter — non-motor symptoms, among them loss of smell, constipation, and a sleep disorder in which people physically act out their dreams, can precede the diagnosis by a decade or more. The condition is, clinically, the visible end of a long invisible process.

Parkinson's is the canonical synucleinopathy: progressive degeneration of the dopaminergic neurons of the substantia nigra pars compacta, with intracellular Lewy bodies — aggregates of misfolded α-synuclein — as the pathological hallmark. The same logic governs Alzheimer's and the prion diseases: a protein that adopts the wrong shape, then templates the misfolding of its neighbors, spreading cell to cell like a slow contagion. As the pigmented neurons die the substantia nigra ("black substance") literally pales, a change visible to the naked eye at autopsy. The resulting dopamine deficit in the basal ganglia — the circuit that selects and smooths intended movement — produces the motor triad: tremor when a limb is at rest, lead-pipe rigidity in the muscles, and the slowed, shrinking movement of bradykinesia, alongside the postural instability that erodes balance as the disease advances. Dopamine normally tips the balance between the basal ganglia's direct pathway, which releases movement, and the indirect pathway, which suppresses it; its loss leaves the brakes dominant, which is why the most disabling sign is not the tremor but the poverty of movement. Onset is typically asymmetric — one hand, one side — and the disease is staged by how far that impairment spreads. As pathology spreads from brainstem to cortex (the Braak staging, which some evidence suggests may begin in the gut and ascend the vagus nerve), patients increasingly develop cognitive impairment; Lewy-body dementia sits on the same disease spectrum, with prominent cognitive and visual-hallucination features alongside motor symptoms. Genetics matters in 10–15% of cases (LRRK2, GBA, SNCA, PARK2, others); the rest are sporadic, with environmental risk factors (pesticide exposure, head trauma) and protective factors (caffeine, exercise, smoking — the latter not a recommendation) more suggestive than determinative. Why dopamine neurons specifically die — the question of selective vulnerability — remains substantially unexplained after a century of research, though their long, unmyelinated axons and heavy metabolic load are leading suspects.